|

HLX43 Clinical Trials

3 actively recruiting trials

▲ +1 trial since June 2026

Also known as: Anti-PD-L1 ADC

Pipeline

Phase 2: 2Phase 2/3: 1

Top Sponsors

  • Shanghai Henlius Biotech3

Indications

  • Cancer3
  • Advanced or Metastatic Squamous Non-Small Cell Lung Cancer1
  • Ovarian Cancer1
  • Esophageal Cancer1
  • Cervical Cancer1

Other3 trials

A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Phase 2/3
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
Phase 2
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.